FeesSafety
Pluang+

California AG drops antitrust suit against Warner Bros. Discovery merger after political backlash.

Market News
27 Sep 2026
New York Post
View Source
Bearish
California AG drops antitrust suit against Warner Bros. Discovery merger after political backlash.

California Attorney General Rob Bonta filed an antitrust lawsuit to block Paramount's purchase of Warner Bros. Discovery, echoing previous failed attempts to block similar media mergers. The lawsuit was widely seen as politically motivated, aiming to score points with the progressive left by targeting media mogul Larry Ellison, a Trump ally. However, backlash from political and Hollywood circles, especially after controversial remarks by activist Mark Ruffalo, pressured Bonta into settling on terms favorable to Ellison without major structural changes. The case highlights the limits of politicized antitrust actions and suggests a cautious approach for future media mergers amid rising streaming costs for consumers.

The political turmoil around Rob Bonta's Paramount-WBD lawsuit provides context for media sector activity on Pluang. As of Sep 27, 2026 14:41 WIB, 21 of 45 media-sector stocks rose while 24 fell. Notable movers include Reddit Inc (RDDT) at USD 149.88 with a 1-day change of -1.87% and 100% sell order activity, Zillow Group Inc Class A (ZG) at USD 29.30 up 1.35% with 100% buy order activity, and TKO Group Holdings Inc (TKO) at USD 182.67 down 1.29%.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Autoliv remains a buy despite weak Q3 2026 with revenue and EPS missing estimates.

Autoliv remains a buy despite weak Q3 2026 with revenue and EPS missing estimates.

Autoliv reported weaker-than-expected Q3 2026 results, with both revenue and earnings per share declining year-over-year. The company faces challenges from falling global light vehicle production and rising auto loan delinquencies. However, Autoliv c...

Company Fundamentals
Neutral
4 hours ago
Meta shifts focus from costly Metaverse to promising AI-driven ad growth and commerce partnerships.

Meta shifts focus from costly Metaverse to promising AI-driven ad growth and commerce partnerships.

Meta Platforms is moving away from expensive investments in superintelligence and the Metaverse, focusing instead on AI-powered advertising and commerce partnerships that offer better monetization prospects. The company's Reality Labs losses are expe...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App